Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
Drug pricing rules and tariffs reshape transfer pricing for IP
In the article “Drug Pricing Rules and Tariffs Reshape Transfer Pricing for IP,” published in Bloomberg Tax, CRA’s Transfer Pricing experts Robin Hart and ...